Beryllium toxicity: Difference between revisions

(Created page with "Beryllium toxicity encompasses two distinct pulmonary diseases caused by exposure to beryllium metal, alloys, or compounds: '''acute beryllium disease''' (ABD), a chemical pneumonitis from high-dose inhalation, and '''chronic beryllium disease''' (CBD, berylliosis), a cell-mediated granulomatous lung disease that is '''clinically, radiographically, and histopathologically indistinguishable from sarcoidosis'''.<ref name="ATS2014">Balmes JR, et al. An official American...")
 
(Strip excess bold)
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
Beryllium toxicity encompasses two distinct pulmonary diseases caused by exposure to beryllium metal, alloys, or compounds: '''acute beryllium disease''' (ABD), a chemical pneumonitis from high-dose inhalation, and '''chronic beryllium disease''' (CBD, berylliosis), a cell-mediated granulomatous lung disease that is '''clinically, radiographically, and histopathologically indistinguishable from [[sarcoidosis]]'''.<ref name="ATS2014">Balmes JR, et al. An official American Thoracic Society statement: diagnosis and management of beryllium sensitivity and chronic beryllium disease. ''Am J Respir Crit Care Med''. 2014;190(10):e34-e59.</ref> ABD is now rare due to workplace exposure limits. CBD remains an active occupational health concern. Beryllium is classified as a '''Group 1 carcinogen''' (lung cancer) by IARC.<ref name="OSHA">Beryllium — Health Effects. Occupational Safety and Health Administration (OSHA).</ref> The ED physician's key role is to consider beryllium exposure in any patient diagnosed with "sarcoidosis" who has occupational exposure, and to manage acute inhalational injury.
==Background==
==Background==
*Beryllium toxicity encompasses two distinct pulmonary diseases caused by exposure to beryllium metal, alloys, or compounds: acute beryllium disease (ABD), a chemical pneumonitis from high-dose inhalation, and chronic beryllium disease (CBD, berylliosis), a cell-mediated granulomatous lung disease that is clinically, radiographically, and histopathologically indistinguishable from [[sarcoidosis]].<ref name="ATS2014">Balmes JR, et al. An official American Thoracic Society statement: diagnosis and management of beryllium sensitivity and chronic beryllium disease. ''Am J Respir Crit Care Med''. 2014;190(10):e34-e59.</ref> ABD is now rare due to workplace exposure limits.
*CBD remains an active occupational health concern.
*Beryllium is classified as a Group 1 carcinogen (lung cancer) by IARC.<ref name="OSHA">Beryllium — Health Effects. Occupational Safety and Health Administration (OSHA).</ref> The ED physician's key role is to consider beryllium exposure in any patient diagnosed with "sarcoidosis" who has occupational exposure, and to manage acute inhalational injury.
*Beryllium is a lightweight metal used in aerospace, defense, nuclear weapons, electronics, telecommunications, dental alloys, high-technology ceramics, metal recycling, and automotive manufacturing<ref name="StatPearls">Berylliosis. ''StatPearls''. NCBI Bookshelf. Updated February 2023.</ref>
*Beryllium is a lightweight metal used in aerospace, defense, nuclear weapons, electronics, telecommunications, dental alloys, high-technology ceramics, metal recycling, and automotive manufacturing<ref name="StatPearls">Berylliosis. ''StatPearls''. NCBI Bookshelf. Updated February 2023.</ref>
*Estimated 134,000 workers in the United States are exposed to beryllium<ref name="Wikipedia">Berylliosis. ''Wikipedia''. Updated January 2026.</ref>
*Estimated 134,000 workers in the United States are exposed to beryllium<ref name="Wikipedia">Berylliosis. ''Wikipedia''. Updated January 2026.</ref>
*'''Two distinct diseases:'''
* Two distinct diseases:
**'''Acute beryllium disease (ABD):''' Direct chemical/toxic pneumonitis from high-dose inhalation; dose-dependent; now rare due to exposure controls; onset within hours to days of heavy exposure; most patients recover with removal from exposure<ref name="NCBI">Epidemiologic and Clinical Studies of Beryllium Sensitization and Chronic Beryllium Disease. In: ''Managing Health Effects of Beryllium Exposure''. National Academies Press; 2008.</ref>
** Acute beryllium disease (ABD): Direct chemical/toxic pneumonitis from high-dose inhalation; dose-dependent; now rare due to exposure controls; onset within hours to days of heavy exposure; most patients recover with removal from exposure<ref name="NCBI">Epidemiologic and Clinical Studies of Beryllium Sensitization and Chronic Beryllium Disease. In: ''Managing Health Effects of Beryllium Exposure''. National Academies Press; 2008.</ref>
**'''Chronic beryllium disease (CBD):''' Cell-mediated (type IV) hypersensitivity reaction; requires prior sensitization; '''not dose-dependent''' — can occur even at levels below OSHA PEL; latency period '''3 months to 30+ years''' from initial exposure<ref name="StatPearls"/>
** Chronic beryllium disease (CBD): Cell-mediated (type IV) hypersensitivity reaction; requires prior sensitization; '''not dose-dependent''' — can occur even at levels below OSHA PEL; latency period '''3 months to 30+ years''' from initial exposure<ref name="StatPearls"/>
*'''Pathogenesis of CBD:'''
* Pathogenesis of CBD:
**Beryllium acts as a hapten → presented by MHC class II (especially '''HLA-DPB1 Glu69''') to CD4+ T cells → T-cell sensitization → upon re-exposure, proliferation of beryllium-specific CD4+ T cells → release of TNF-α, IL-2, IFN-γ → '''noncaseating granuloma formation'''<ref name="ATS2014"/>
**Beryllium acts as a hapten → presented by MHC class II (especially HLA-DPB1 Glu69) to CD4+ T cells → T-cell sensitization → upon re-exposure, proliferation of beryllium-specific CD4+ T cells → release of TNF-α, IL-2, IFN-γ → noncaseating granuloma formation<ref name="ATS2014"/>
**Essentially identical pathogenesis to sarcoidosis (granulomatous inflammation driven by CD4+ T-cell response to an antigen)
**Essentially identical pathogenesis to sarcoidosis (granulomatous inflammation driven by CD4+ T-cell response to an antigen)
*'''Beryllium sensitization (BeS):''' Immune sensitization without clinical disease; detected by beryllium lymphocyte proliferation test (BeLPT); 2–6% of exposed workers become sensitized; among sensitized workers, ~66% progress to CBD<ref name="StatPearls"/>
* Beryllium sensitization (BeS): Immune sensitization without clinical disease; detected by beryllium lymphocyte proliferation test (BeLPT); 2–6% of exposed workers become sensitized; among sensitized workers, ~66% progress to CBD<ref name="StatPearls"/>
*Skin exposure (not just inhalation) may cause sensitization<ref name="OSHA"/>
*Skin exposure (not just inhalation) may cause sensitization<ref name="OSHA"/>
*'''Chelation therapy is ineffective''' — beryllium is poorly soluble and persists in the body for the individual's lifetime<ref name="ATS2014"/>
* Chelation therapy is ineffective — beryllium is poorly soluble and persists in the body for the individual's lifetime<ref name="ATS2014"/>
*OSHA permissible exposure limit: 0.2 µg/m³ (8-hour TWA); cases still occur below this threshold<ref name="OSHA"/>
*OSHA permissible exposure limit: 0.2 µg/m³ (8-hour TWA); cases still occur below this threshold<ref name="OSHA"/>


==Clinical Features==
==Clinical Features==
'''Acute beryllium disease (rare):'''
Acute beryllium disease (rare):
*Onset hours to days after heavy inhalation exposure
*Onset hours to days after heavy inhalation exposure
*Severe cough, dyspnea, chest tightness
*Severe cough, dyspnea, chest tightness
Line 24: Line 25:
*Most patients recover over weeks to months if removed from exposure, though may recur with re-exposure<ref name="NCBI"/>
*Most patients recover over weeks to months if removed from exposure, though may recur with re-exposure<ref name="NCBI"/>


'''Chronic beryllium disease:'''
Chronic beryllium disease:
*'''Insidious onset''' — latency period of months to '''decades''' (mean ~10 years) after initial exposure<ref name="StatPearls"/>
* Insidious onset — latency period of months to '''decades''' (mean ~10 years) after initial exposure<ref name="StatPearls"/>
*Progressive '''dyspnea on exertion''' (most common symptom)
*Progressive dyspnea on exertion (most common symptom)
*Persistent dry cough
*Persistent dry cough
*Fatigue, weight loss
*Fatigue, weight loss
*Fever, night sweats (mimics [[tuberculosis]] or lymphoma)
*Fever, night sweats (mimics [[tuberculosis]] or lymphoma)
*Chest pain (uncommon)
*Chest pain (uncommon)
*'''Physical exam:'''
* Physical exam:
**May be '''normal''' early in disease (many cases detected by surveillance BeLPT before symptoms develop)
**May be normal early in disease (many cases detected by surveillance BeLPT before symptoms develop)
**Bibasal inspiratory crackles
**Bibasal inspiratory crackles
**Lymphadenopathy
**Lymphadenopathy
**Hepatosplenomegaly (rare)
**Hepatosplenomegaly (rare)
*'''Extrapulmonary manifestations''' (less common than sarcoidosis):
* Extrapulmonary manifestations (less common than sarcoidosis):
**'''Skin:''' Granulomatous skin lesions — most common extrapulmonary manifestation; contact dermatitis; subcutaneous nodules at sites of skin implantation (embedded beryllium particles)<ref name="CBD">Rossman MD. Chronic beryllium disease: diagnosis and management. ''Environ Health Perspect''. 1996;104(Suppl 5):945-947.</ref>
** Skin: Granulomatous skin lesions — most common extrapulmonary manifestation; contact dermatitis; subcutaneous nodules at sites of skin implantation (embedded beryllium particles)<ref name="CBD">Rossman MD. Chronic beryllium disease: diagnosis and management. ''Environ Health Perspect''. 1996;104(Suppl 5):945-947.</ref>
**Granulomatous hepatitis
**Granulomatous hepatitis
**[[Hypercalcemia]]
**[[Hypercalcemia]]
Line 43: Line 44:
**Uveitis (less common than in sarcoidosis)
**Uveitis (less common than in sarcoidosis)


'''Beryllium dermatitis:'''
Beryllium dermatitis:
*Contact dermatitis from skin exposure to beryllium salts
*Contact dermatitis from skin exposure to beryllium salts
*Patients who develop beryllium contact dermatitis are at '''high risk''' for beryllium sensitization and subsequent CBD<ref name="ClevelandClinic">Berylliosis (Chronic Beryllium Disease). Cleveland Clinic. Updated November 2025.</ref>
*Patients who develop beryllium contact dermatitis are at high risk for beryllium sensitization and subsequent CBD<ref name="ClevelandClinic">Berylliosis (Chronic Beryllium Disease). Cleveland Clinic. Updated November 2025.</ref>


==Differential Diagnosis==
==Differential Diagnosis==
*'''[[Sarcoidosis]]''' — the '''most important differential'''; clinically indistinguishable from CBD; any patient diagnosed with "sarcoidosis" who has a history of beryllium exposure should be evaluated for CBD with BeLPT<ref name="Merck">Beryllium Disease. ''Merck Manual Professional Edition''. Updated October 2023.</ref>
* [[Sarcoidosis]] — the most important differential; clinically indistinguishable from CBD; any patient diagnosed with "sarcoidosis" who has a history of beryllium exposure should be evaluated for CBD with BeLPT<ref name="Merck">Beryllium Disease. ''Merck Manual Professional Edition''. Updated October 2023.</ref>
*[[Tuberculosis]] (caseating granulomas; AFB stain/culture positive; unlike CBD which has noncaseating granulomas)
*[[Tuberculosis]] (caseating granulomas; AFB stain/culture positive; unlike CBD which has noncaseating granulomas)
*[[Hypersensitivity pneumonitis]] (exposure history differs; bronchiolocentric poorly formed granulomas vs. well-formed granulomas of CBD)
*[[Hypersensitivity pneumonitis]] (exposure history differs; bronchiolocentric poorly formed granulomas vs. well-formed granulomas of CBD)
Line 56: Line 57:
*Lymphoma (hilar lymphadenopathy, constitutional symptoms)
*Lymphoma (hilar lymphadenopathy, constitutional symptoms)
*[[Lung cancer]] (beryllium is a Group 1 carcinogen; may coexist with CBD)
*[[Lung cancer]] (beryllium is a Group 1 carcinogen; may coexist with CBD)
*'''For acute beryllium disease:'''
* For acute beryllium disease:
**[[Toxic inhalation]] injury (chlorine, phosgene, metal fume fever)
**[[Toxic inhalation]] injury (chlorine, phosgene, metal fume fever)
**Acute [[eosinophilic pneumonia]]
**Acute [[eosinophilic pneumonia]]
**[[Pneumonia]]
**[[Pneumonia]]
**[[ARDS]] from other causes
**[[ARDS]] from other causes
{{Pulmonary fibrosis differential}}


==Evaluation==
==Evaluation==
===Workup===
===Workup===
'''History — the most critical diagnostic tool:'''
History — the most critical diagnostic tool:
*'''Detailed occupational history:''' Current and all prior employment; specifically ask about aerospace, defense, nuclear, electronics, telecommunications, dental laboratory, ceramics, metal alloy machining, metal recycling, and jewelry work
* Detailed occupational history: Current and all prior employment; specifically ask about aerospace, defense, nuclear, electronics, telecommunications, dental laboratory, ceramics, metal alloy machining, metal recycling, and jewelry work
*'''Do not rely on the patient knowing they were exposed''' — many workers are unaware that beryllium is present in their workplace (copper-beryllium alloys, aluminum-beryllium alloys are common); even clerical workers in beryllium facilities have developed sensitization<ref name="Wikipedia"/>
*'''Do not rely on the patient knowing they were exposed''' — many workers are unaware that beryllium is present in their workplace (copper-beryllium alloys, aluminum-beryllium alloys are common); even clerical workers in beryllium facilities have developed sensitization<ref name="Wikipedia"/>
*Duration and intensity of exposure (though CBD can occur at very low levels)
*Duration and intensity of exposure (though CBD can occur at very low levels)
Line 71: Line 75:
*Latency period may be very long — ask about exposures decades ago
*Latency period may be very long — ask about exposures decades ago


'''Laboratory (ED):'''
Laboratory (ED):
*CBC, CMP (renal function, calcium)
*CBC, CMP (renal function, calcium)
*'''Serum calcium:''' Hypercalcemia may occur (granulomatous production of 1,25-dihydroxyvitamin D, as in sarcoidosis)
* Serum calcium: Hypercalcemia may occur (granulomatous production of 1,25-dihydroxyvitamin D, as in sarcoidosis)
*ACE level: Often elevated (same mechanism as sarcoidosis; nonspecific)
*ACE level: Often elevated (same mechanism as sarcoidosis; nonspecific)
*ABG/VBG: Hypoxemia, especially with exercise
*ABG/VBG: Hypoxemia, especially with exercise
*ESR/CRP: May be elevated
*ESR/CRP: May be elevated
*'''Beryllium lymphocyte proliferation test (BeLPT):''' NOT an ED test — requires specialized laboratory; performed on peripheral blood or BAL fluid; detects beryllium-specific T-cell sensitization; forms the basis of diagnosis<ref name="ATS2014"/>
* Beryllium lymphocyte proliferation test (BeLPT): NOT an ED test — requires specialized laboratory; performed on peripheral blood or BAL fluid; detects beryllium-specific T-cell sensitization; forms the basis of diagnosis<ref name="ATS2014"/>
**'''Two abnormal blood BeLPTs''' or '''one abnormal BAL BeLPT''' confirms beryllium sensitization
** Two abnormal blood BeLPTs or one abnormal BAL BeLPT confirms beryllium sensitization
**Sensitivity ~75–90% for blood BeLPT; BAL BeLPT is more sensitive
**Sensitivity ~75–90% for blood BeLPT; BAL BeLPT is more sensitive
*'''Note:''' There are no useful serum or urine beryllium levels for clinical diagnosis — body burden is not reflected by blood/urine concentrations, and beryllium is poorly soluble<ref name="ATS2014"/>
* Note: There are no useful serum or urine beryllium levels for clinical diagnosis — body burden is not reflected by blood/urine concentrations, and beryllium is poorly soluble<ref name="ATS2014"/>


'''Imaging:'''
Imaging:


''Chest X-ray:''
''Chest X-ray:''
*May be '''normal''' early in CBD<ref name="Merck"/>
*May be normal early in CBD<ref name="Merck"/>
*Abnormalities often '''indistinguishable from sarcoidosis:'''
*Abnormalities often indistinguishable from sarcoidosis:
**Bilateral hilar and mediastinal lymphadenopathy
**Bilateral hilar and mediastinal lymphadenopathy
**Diffuse reticulonodular infiltrates
**Diffuse reticulonodular infiltrates
Line 99: Line 103:
*May be normal in early CBD<ref name="Merck"/>
*May be normal in early CBD<ref name="Merck"/>


'''Pulmonary function tests''' (outpatient):
Pulmonary function tests (outpatient):
*'''Restrictive''' pattern most common (reduced FVC, reduced TLC)
* Restrictive pattern most common (reduced FVC, reduced TLC)
*Reduced DLCO (often the earliest PFT abnormality)<ref name="StatPearls"/>
*Reduced DLCO (often the earliest PFT abnormality)<ref name="StatPearls"/>
*May show obstructive or mixed pattern
*May show obstructive or mixed pattern
Line 106: Line 110:


===Diagnosis===
===Diagnosis===
*'''Definitive diagnosis of CBD''' requires:<ref name="ATS2014"/>
* Definitive diagnosis of CBD requires:<ref name="ATS2014"/>
**(1) History of beryllium exposure
**(1) History of beryllium exposure
**(2) Positive BeLPT (beryllium sensitization confirmed)
**(2) Positive BeLPT (beryllium sensitization confirmed)
**(3) Granulomatous inflammation on lung biopsy
**(3) Granulomatous inflammation on lung biopsy
*'''Probable CBD''' can be diagnosed with two of these three criteria when the third is unavailable
* Probable CBD can be diagnosed with two of these three criteria when the third is unavailable
*'''In the ED:''' Definitive diagnosis is not possible — the key is to '''consider the diagnosis''' in any patient presenting with a sarcoidosis-like picture who has occupational beryllium exposure history
* In the ED: Definitive diagnosis is not possible — the key is to consider the diagnosis in any patient presenting with a sarcoidosis-like picture who has occupational beryllium exposure history
*Any patient diagnosed with [[sarcoidosis]] who has '''any history of beryllium exposure''' should be referred for BeLPT testing to rule out CBD<ref name="Merck"/>
*Any patient diagnosed with [[sarcoidosis]] who has any history of beryllium exposure should be referred for BeLPT testing to rule out CBD<ref name="Merck"/>
*Lung biopsy (transbronchial or surgical) shows '''noncaseating granulomas''' identical to sarcoidosis; special stains and cultures are negative for mycobacteria and fungi<ref name="StatPearls"/>
*Lung biopsy (transbronchial or surgical) shows '''noncaseating granulomas''' identical to sarcoidosis; special stains and cultures are negative for mycobacteria and fungi<ref name="StatPearls"/>
*BAL typically shows lymphocytosis with increased CD4:CD8 ratio (similar to sarcoidosis)
*BAL typically shows lymphocytosis with increased CD4:CD8 ratio (similar to sarcoidosis)


==Management==
==Management==
'''Acute beryllium disease (chemical pneumonitis):'''
Acute beryllium disease (chemical pneumonitis):
*'''Remove from exposure''' immediately
* Remove from exposure immediately
*Supplemental O2; high-flow or non-invasive ventilation as needed
*Supplemental O2; high-flow or non-invasive ventilation as needed
*Intubation and mechanical ventilation for [[ARDS]]
*Intubation and mechanical ventilation for [[ARDS]]
Line 126: Line 130:
*Supportive care: IV fluids, monitoring
*Supportive care: IV fluids, monitoring
*Skin decontamination if dermal exposure (copious water irrigation; embedded beryllium particles may require surgical excision to prevent chronic granulomatous skin lesions)
*Skin decontamination if dermal exposure (copious water irrigation; embedded beryllium particles may require surgical excision to prevent chronic granulomatous skin lesions)
*'''Chelation therapy is NOT effective''' for beryllium — the metal is poorly soluble and persists in tissue indefinitely<ref name="ATS2014"/>
* Chelation therapy is NOT effective for beryllium — the metal is poorly soluble and persists in tissue indefinitely<ref name="ATS2014"/>


'''Chronic beryllium disease:'''
Chronic beryllium disease:
*'''Remove from further beryllium exposure''' — though evidence that removal alone improves outcomes is limited; disease frequently progresses even after exposure ceases<ref name="ATS2014"/>
* Remove from further beryllium exposure — though evidence that removal alone improves outcomes is limited; disease frequently progresses even after exposure ceases<ref name="ATS2014"/>
*'''Corticosteroids''' — first-line pharmacotherapy:<ref name="ATS2014"/>
* Corticosteroids — first-line pharmacotherapy:<ref name="ATS2014"/>
**Prednisone 20–40 mg daily or every other day for 3–6 months
**Prednisone 20–40 mg daily or every other day for 3–6 months
**Taper guided by symptoms, PFTs, and gas exchange
**Taper guided by symptoms, PFTs, and gas exchange
**Long-term low-dose maintenance may be necessary
**Long-term low-dose maintenance may be necessary
*'''Steroid-sparing agents''' for patients who fail or cannot tolerate corticosteroids:
* Steroid-sparing agents for patients who fail or cannot tolerate corticosteroids:
**Methotrexate (7.5 mg/week with folic acid; monitor CBC and LFTs every 8–12 weeks)<ref name="StatPearls"/>
**Methotrexate (7.5 mg/week with folic acid; monitor CBC and LFTs every 8–12 weeks)<ref name="StatPearls"/>
**Azathioprine
**Azathioprine
Line 142: Line 146:
*Pulmonary rehabilitation
*Pulmonary rehabilitation
*Lung transplantation for end-stage disease (limited experience; effectiveness uncertain)<ref name="ATS2014"/>
*Lung transplantation for end-stage disease (limited experience; effectiveness uncertain)<ref name="ATS2014"/>
*'''Beryllium sensitization without CBD:''' No treatment required; remove from exposure; periodic monitoring with PFTs, CXR, and BeLPT for progression to CBD<ref name="NORD"/>
* Beryllium sensitization without CBD: No treatment required; remove from exposure; periodic monitoring with PFTs, CXR, and BeLPT for progression to CBD<ref name="NORD"/>
*'''Lifelong follow-up:''' Serial PFTs, ABGs, CXR; patients with CBD require ongoing monitoring even if asymptomatic<ref name="StatPearls"/>
* Lifelong follow-up: Serial PFTs, ABGs, CXR; patients with CBD require ongoing monitoring even if asymptomatic<ref name="StatPearls"/>


'''Reporting and occupational considerations:'''
Reporting and occupational considerations:
*CBD is a '''compensable occupational illness''' — document exposure history thoroughly
*CBD is a compensable occupational illness — document exposure history thoroughly
*Federal workers exposed at DOE facilities may be eligible for compensation under the Energy Employees Occupational Illness Compensation Program<ref name="ATS2014"/>
*Federal workers exposed at DOE facilities may be eligible for compensation under the Energy Employees Occupational Illness Compensation Program<ref name="ATS2014"/>
*Report to OSHA / state occupational health authorities as appropriate
*Report to OSHA / state occupational health authorities as appropriate
*Beryllium is a '''known human carcinogen''' — patients with CBD should be counseled about increased lung cancer risk and offered appropriate cancer surveillance<ref name="OSHA"/>
*Beryllium is a known human carcinogen — patients with CBD should be counseled about increased lung cancer risk and offered appropriate cancer surveillance<ref name="OSHA"/>


==Disposition==
==Disposition==
*'''Admit:'''
* Admit:
**Acute beryllium disease with significant hypoxemia, respiratory distress, or chemical pneumonitis
**Acute beryllium disease with significant hypoxemia, respiratory distress, or chemical pneumonitis
**Suspected ARDS from acute inhalation
**Suspected ARDS from acute inhalation
**New presentation of CBD with respiratory failure or significant hypoxemia
**New presentation of CBD with respiratory failure or significant hypoxemia
**Severe exacerbation of known CBD
**Severe exacerbation of known CBD
*'''Discharge with close follow-up:'''
* Discharge with close follow-up:
**Stable known CBD patient with mild symptoms at baseline
**Stable known CBD patient with mild symptoms at baseline
**Suspected CBD in a stable patient — arrange:
**Suspected CBD in a stable patient — arrange:
Line 165: Line 169:
***PFTs with DLCO
***PFTs with DLCO
**Minor skin exposure — irrigate thoroughly; refer to occupational medicine for BeLPT screening
**Minor skin exposure — irrigate thoroughly; refer to occupational medicine for BeLPT screening
*'''Discharge counseling:'''
* Discharge counseling:
**Return for worsening dyspnea, fever, or new respiratory symptoms
**Return for worsening dyspnea, fever, or new respiratory symptoms
**'''Avoid further beryllium exposure''' — discuss with employer and occupational health
** Avoid further beryllium exposure — discuss with employer and occupational health
**If diagnosed with sarcoidosis previously and any beryllium exposure history exists, inform referring physician to order BeLPT
**If diagnosed with sarcoidosis previously and any beryllium exposure history exists, inform referring physician to order BeLPT
**Smoking cessation (beryllium is a lung carcinogen; smoking compounds risk)
**Smoking cessation (beryllium is a lung carcinogen; smoking compounds risk)

Latest revision as of 09:28, 22 March 2026

Background

  • Beryllium toxicity encompasses two distinct pulmonary diseases caused by exposure to beryllium metal, alloys, or compounds: acute beryllium disease (ABD), a chemical pneumonitis from high-dose inhalation, and chronic beryllium disease (CBD, berylliosis), a cell-mediated granulomatous lung disease that is clinically, radiographically, and histopathologically indistinguishable from sarcoidosis.[1] ABD is now rare due to workplace exposure limits.
  • CBD remains an active occupational health concern.
  • Beryllium is classified as a Group 1 carcinogen (lung cancer) by IARC.[2] The ED physician's key role is to consider beryllium exposure in any patient diagnosed with "sarcoidosis" who has occupational exposure, and to manage acute inhalational injury.
  • Beryllium is a lightweight metal used in aerospace, defense, nuclear weapons, electronics, telecommunications, dental alloys, high-technology ceramics, metal recycling, and automotive manufacturing[3]
  • Estimated 134,000 workers in the United States are exposed to beryllium[4]
  • Two distinct diseases:
    • Acute beryllium disease (ABD): Direct chemical/toxic pneumonitis from high-dose inhalation; dose-dependent; now rare due to exposure controls; onset within hours to days of heavy exposure; most patients recover with removal from exposure[5]
    • Chronic beryllium disease (CBD): Cell-mediated (type IV) hypersensitivity reaction; requires prior sensitization; not dose-dependent — can occur even at levels below OSHA PEL; latency period 3 months to 30+ years from initial exposure[3]
  • Pathogenesis of CBD:
    • Beryllium acts as a hapten → presented by MHC class II (especially HLA-DPB1 Glu69) to CD4+ T cells → T-cell sensitization → upon re-exposure, proliferation of beryllium-specific CD4+ T cells → release of TNF-α, IL-2, IFN-γ → noncaseating granuloma formation[1]
    • Essentially identical pathogenesis to sarcoidosis (granulomatous inflammation driven by CD4+ T-cell response to an antigen)
  • Beryllium sensitization (BeS): Immune sensitization without clinical disease; detected by beryllium lymphocyte proliferation test (BeLPT); 2–6% of exposed workers become sensitized; among sensitized workers, ~66% progress to CBD[3]
  • Skin exposure (not just inhalation) may cause sensitization[2]
  • Chelation therapy is ineffective — beryllium is poorly soluble and persists in the body for the individual's lifetime[1]
  • OSHA permissible exposure limit: 0.2 µg/m³ (8-hour TWA); cases still occur below this threshold[2]

Clinical Features

Acute beryllium disease (rare):

  • Onset hours to days after heavy inhalation exposure
  • Severe cough, dyspnea, chest tightness
  • Chemical pneumonitis → pulmonary edema → ARDS in severe cases[5]
  • Rhinitis, pharyngitis, tracheobronchitis with upper airway irritation
  • May be fulminant and fatal if exposure is massive
  • Most patients recover over weeks to months if removed from exposure, though may recur with re-exposure[5]

Chronic beryllium disease:

  • Insidious onset — latency period of months to decades (mean ~10 years) after initial exposure[3]
  • Progressive dyspnea on exertion (most common symptom)
  • Persistent dry cough
  • Fatigue, weight loss
  • Fever, night sweats (mimics tuberculosis or lymphoma)
  • Chest pain (uncommon)
  • Physical exam:
    • May be normal early in disease (many cases detected by surveillance BeLPT before symptoms develop)
    • Bibasal inspiratory crackles
    • Lymphadenopathy
    • Hepatosplenomegaly (rare)
  • Extrapulmonary manifestations (less common than sarcoidosis):
    • Skin: Granulomatous skin lesions — most common extrapulmonary manifestation; contact dermatitis; subcutaneous nodules at sites of skin implantation (embedded beryllium particles)[6]
    • Granulomatous hepatitis
    • Hypercalcemia
    • Nephrolithiasis (kidney stones)
    • Uveitis (less common than in sarcoidosis)

Beryllium dermatitis:

  • Contact dermatitis from skin exposure to beryllium salts
  • Patients who develop beryllium contact dermatitis are at high risk for beryllium sensitization and subsequent CBD[7]

Differential Diagnosis


Pulmonary Fibrosis

Evaluation

Workup

History — the most critical diagnostic tool:

  • Detailed occupational history: Current and all prior employment; specifically ask about aerospace, defense, nuclear, electronics, telecommunications, dental laboratory, ceramics, metal alloy machining, metal recycling, and jewelry work
  • Do not rely on the patient knowing they were exposed — many workers are unaware that beryllium is present in their workplace (copper-beryllium alloys, aluminum-beryllium alloys are common); even clerical workers in beryllium facilities have developed sensitization[4]
  • Duration and intensity of exposure (though CBD can occur at very low levels)
  • Household/bystander exposure (contaminated work clothing brought home)
  • Latency period may be very long — ask about exposures decades ago

Laboratory (ED):

  • CBC, CMP (renal function, calcium)
  • Serum calcium: Hypercalcemia may occur (granulomatous production of 1,25-dihydroxyvitamin D, as in sarcoidosis)
  • ACE level: Often elevated (same mechanism as sarcoidosis; nonspecific)
  • ABG/VBG: Hypoxemia, especially with exercise
  • ESR/CRP: May be elevated
  • Beryllium lymphocyte proliferation test (BeLPT): NOT an ED test — requires specialized laboratory; performed on peripheral blood or BAL fluid; detects beryllium-specific T-cell sensitization; forms the basis of diagnosis[1]
    • Two abnormal blood BeLPTs or one abnormal BAL BeLPT confirms beryllium sensitization
    • Sensitivity ~75–90% for blood BeLPT; BAL BeLPT is more sensitive
  • Note: There are no useful serum or urine beryllium levels for clinical diagnosis — body burden is not reflected by blood/urine concentrations, and beryllium is poorly soluble[1]

Imaging:

Chest X-ray:

  • May be normal early in CBD[8]
  • Abnormalities often indistinguishable from sarcoidosis:
    • Bilateral hilar and mediastinal lymphadenopathy
    • Diffuse reticulonodular infiltrates
    • Upper-lobe predominance of parenchymal opacities
  • Acute beryllium disease: diffuse bilateral hazy/ground-glass opacities → frank pulmonary edema pattern[5]

HRCT (more sensitive than CXR):

  • Ground-glass opacities
  • Small parenchymal nodules (along bronchovascular bundles and subpleural — identical to sarcoidosis)
  • Mediastinal and hilar lymphadenopathy
  • Fibrosis, honeycombing in advanced disease
  • May be normal in early CBD[8]

Pulmonary function tests (outpatient):

  • Restrictive pattern most common (reduced FVC, reduced TLC)
  • Reduced DLCO (often the earliest PFT abnormality)[3]
  • May show obstructive or mixed pattern
  • Exercise-induced desaturation (useful for detecting early disease)

Diagnosis

  • Definitive diagnosis of CBD requires:[1]
    • (1) History of beryllium exposure
    • (2) Positive BeLPT (beryllium sensitization confirmed)
    • (3) Granulomatous inflammation on lung biopsy
  • Probable CBD can be diagnosed with two of these three criteria when the third is unavailable
  • In the ED: Definitive diagnosis is not possible — the key is to consider the diagnosis in any patient presenting with a sarcoidosis-like picture who has occupational beryllium exposure history
  • Any patient diagnosed with sarcoidosis who has any history of beryllium exposure should be referred for BeLPT testing to rule out CBD[8]
  • Lung biopsy (transbronchial or surgical) shows noncaseating granulomas identical to sarcoidosis; special stains and cultures are negative for mycobacteria and fungi[3]
  • BAL typically shows lymphocytosis with increased CD4:CD8 ratio (similar to sarcoidosis)

Management

Acute beryllium disease (chemical pneumonitis):

  • Remove from exposure immediately
  • Supplemental O2; high-flow or non-invasive ventilation as needed
  • Intubation and mechanical ventilation for ARDS
  • Systemic corticosteroids (methylprednisolone IV or prednisone PO) for significant pulmonary inflammation
  • Bronchodilators for bronchospasm
  • Standard ARDS management if severe (low tidal volume ventilation, prone positioning)
  • Supportive care: IV fluids, monitoring
  • Skin decontamination if dermal exposure (copious water irrigation; embedded beryllium particles may require surgical excision to prevent chronic granulomatous skin lesions)
  • Chelation therapy is NOT effective for beryllium — the metal is poorly soluble and persists in tissue indefinitely[1]

Chronic beryllium disease:

  • Remove from further beryllium exposure — though evidence that removal alone improves outcomes is limited; disease frequently progresses even after exposure ceases[1]
  • Corticosteroids — first-line pharmacotherapy:[1]
    • Prednisone 20–40 mg daily or every other day for 3–6 months
    • Taper guided by symptoms, PFTs, and gas exchange
    • Long-term low-dose maintenance may be necessary
  • Steroid-sparing agents for patients who fail or cannot tolerate corticosteroids:
    • Methotrexate (7.5 mg/week with folic acid; monitor CBC and LFTs every 8–12 weeks)[3]
    • Azathioprine
    • Mycophenolate mofetil
    • Infliximab (under investigation)[9]
  • Supplemental O2 to maintain SpO2 ≥90%
  • Pulmonary rehabilitation
  • Lung transplantation for end-stage disease (limited experience; effectiveness uncertain)[1]
  • Beryllium sensitization without CBD: No treatment required; remove from exposure; periodic monitoring with PFTs, CXR, and BeLPT for progression to CBD[9]
  • Lifelong follow-up: Serial PFTs, ABGs, CXR; patients with CBD require ongoing monitoring even if asymptomatic[3]

Reporting and occupational considerations:

  • CBD is a compensable occupational illness — document exposure history thoroughly
  • Federal workers exposed at DOE facilities may be eligible for compensation under the Energy Employees Occupational Illness Compensation Program[1]
  • Report to OSHA / state occupational health authorities as appropriate
  • Beryllium is a known human carcinogen — patients with CBD should be counseled about increased lung cancer risk and offered appropriate cancer surveillance[2]

Disposition

  • Admit:
    • Acute beryllium disease with significant hypoxemia, respiratory distress, or chemical pneumonitis
    • Suspected ARDS from acute inhalation
    • New presentation of CBD with respiratory failure or significant hypoxemia
    • Severe exacerbation of known CBD
  • Discharge with close follow-up:
    • Stable known CBD patient with mild symptoms at baseline
    • Suspected CBD in a stable patient — arrange:
      • Occupational medicine or pulmonology referral (ideally to a center with beryllium disease expertise) within 1–2 weeks
      • BeLPT testing (requires specialized lab — coordinate with occupational medicine)
      • HRCT if not performed
      • PFTs with DLCO
    • Minor skin exposure — irrigate thoroughly; refer to occupational medicine for BeLPT screening
  • Discharge counseling:
    • Return for worsening dyspnea, fever, or new respiratory symptoms
    • Avoid further beryllium exposure — discuss with employer and occupational health
    • If diagnosed with sarcoidosis previously and any beryllium exposure history exists, inform referring physician to order BeLPT
    • Smoking cessation (beryllium is a lung carcinogen; smoking compounds risk)

See Also

External Links

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 Balmes JR, et al. An official American Thoracic Society statement: diagnosis and management of beryllium sensitivity and chronic beryllium disease. Am J Respir Crit Care Med. 2014;190(10):e34-e59.
  2. ↑ 2.0 2.1 2.2 2.3 Beryllium — Health Effects. Occupational Safety and Health Administration (OSHA).
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 Berylliosis. StatPearls. NCBI Bookshelf. Updated February 2023.
  4. ↑ 4.0 4.1 Berylliosis. Wikipedia. Updated January 2026.
  5. ↑ 5.0 5.1 5.2 5.3 Epidemiologic and Clinical Studies of Beryllium Sensitization and Chronic Beryllium Disease. In: Managing Health Effects of Beryllium Exposure. National Academies Press; 2008.
  6. ↑ Rossman MD. Chronic beryllium disease: diagnosis and management. Environ Health Perspect. 1996;104(Suppl 5):945-947.
  7. ↑ Berylliosis (Chronic Beryllium Disease). Cleveland Clinic. Updated November 2025.
  8. ↑ 8.0 8.1 8.2 8.3 Beryllium Disease. Merck Manual Professional Edition. Updated October 2023.
  9. ↑ 9.0 9.1 Berylliosis. National Organization for Rare Disorders (NORD). Updated January 2023.
Retrieved from "https://www.wikem.org/w/index.php?title=Beryllium_toxicity&oldid=389168"